Brain Tumor Centers

Find U.S. facilities with actively recruiting interventional brain-tumor trials. Choose one state at a time; facility details load only after you select a facility.

Back to facilities in Washington

Fred Hutch Cancer Center

Seattle, Washington 98109

Reported site contacts

Angela Castellanos, MD — principal investigator
Trial: NCT05636618

Heather White — contact
nucmedresearch@fredhutch.org
206-667-5534
Trial: NCT05636618

Jordan Gauthier, MD — contact
jgauthier@fredhutch.org
Trial: NCT04792489

Madhuri Poduri — contact
mpoduri@fredhutch.org
206-667-3691
Trial: NCT05303519

Rebecca Wood — contact
rwood1@seattlecca.org
206-606-6970
Trial: NCT05786924

Tyler Lanman, MD — principal investigator
Trial: NCT05303519

Recruiting trials at this facility

• A Phase 1/1b Study of IAM1363 in HER2 Cancers (NCT06253871)
  HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer, Brain Metastases From Solid Tumors, Brain Metastases From HER2 and Breast Cancer, CNS Metastases, HER2-Positive Solid Tumors, NSCLC (Non-small Cell Lung Cancer), HER2-positive Bladder Cancer, HER2-positive Colorectal Cancer, HER2 + Gastric Cancer, HER2-positive Gastroesophageal Cancer
• A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma (NCT05765812)
  Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype, Astrocytoma, Grade III
• DALY II USA/ MB-CART2019.1 for DLBCL (NCT04792489)
  Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B Cell Lymphoma, High Grade B-cell Lymphoma (HGBCL), Primary Mediastinal B-cell Lymphoma (PMBCL), Transformed Lymphoma, Central Nervous System Lymphoma, Mantle Cell Lymphoma (MCL), Richter Transformation, Transplant-ineligible 2nd Line DLBCL
• Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies (NCT05786924)
  Non-small Cell Lung Cancer, Histiocytic Neoplasm, Histiocytosis, BRAF Gene Mutation, BRAF V600E, BRAF V600 Mutation, BRAF Mutation-Related Tumors, BRAF, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Lung Cancer, Recurrent Lung Cancer, Recurrent Lung Non-Small Cell Carcinoma, NSCLC, Solid Tumor, Solid Carcinoma, KRAS G12D, KRAS G12V, KRAS Mutation-Related Tumors, NRAS Gene Mutation, Thyroid Cancer, Thyroid Carcinoma, Colorectal Cancer, Colorectal Carcinoma, Recurrent Histiocytic and Dendritic Cell Neoplasm, Brain Metastases, Recurrent NSCLC, KRAS G13C, Acquired Resistance to KRAS G12C Inhibitor, KRAS G12A, KRAS G12F, KRAS G12R, KRAS G13D
• SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance) (NCT05303519)
  Glioma, Astrocytoma, Grade IV, IDH1-mutant Glioma, Astrocytoma, IDH-Mutant, Grade 3, Astrocytoma, IDH-Mutant, Grade 4, Astrocytoma, IDH-Mutant, Grade 2, Oligodendroglioma, Oligodendroglioma, IDH-Mutant and 1p/19q-Codeleted
• Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors (NCT05636618)
  Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic, Gastroenteropancreatic Neuroendocrine Tumor, Bronchial Neuroendocrine Tumor, Paraganglioma, Pheochromocytoma, Meningioma